Summit Therapeutics Inc.
SMMT
$17.46
-$1.45-7.67%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.80% | 6.84% | -38.90% | -18.89% | -71.93% |
| Total Depreciation and Amortization | 10.00% | 0.00% | -25.93% | -10.00% | -6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.27% | -30.32% | 167.27% | 7.15% | 293.80% |
| Change in Net Operating Assets | -107.65% | 198.37% | -28.44% | -51.03% | 105.12% |
| Cash from Operations | -60.65% | 8.20% | -9.52% | -54.86% | -30.62% |
| Capital Expenditure | 75.86% | 7.94% | -1,475.00% | -100.00% | 96.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 176.91% | 45.73% | -1,106.37% | -67.19% | 1,864.35% |
| Cash from Investing | 176.86% | 45.71% | -1,106.89% | -67.19% | 1,837.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 67.55% | -- | -- | -- | -- |
| Issuance of Common Stock | -99.68% | 39.67% | 41,180.82% | -92.94% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -200.00% |
| Cash from Financing | -111.57% | 1.96% | 41,180.82% | -92.24% | 2,630.13% |
| Foreign Exchange rate Adjustments | -194.74% | 850.00% | 133.33% | -113.24% | 260.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -83.03% | 298.87% | -234.80% | -120.60% | 359.95% |
